oxford—astrazeneca vaccine manufactured ? the oxford—astrazeneca vaccine manufactured? the concern is the supply chain could take longer to reach some parts of the world. that's something that is not controlled by the university of oxford but is determined by astrazeneca. one of the reasons the university partnered with astrazeneca is because it has an extensive network of manufacturing capabilities and supply and logistics around the world, which means that it's going to be very rapidly upscaling production and delivering the vaccine across the world. for the uk vaccine, and this will be manufactured both in the uk and the netherlands, the real advantage of the oxford vaccine is it can be stored between two and 8 degrees, so in a normalfridge, and thatis degrees, so in a normalfridge, and that is how most vaccines are normally rolled out across the country and the world. childhood immunisations or travel vaccines are usually stored at that temperature. we can tap into the existing logistics networks used by health ca re logistics networks used by health care profession

>> i think it's the price that astrazeneca is paying for these assets. the deal values alexion at 13.5 times p\e. so they are paying a hefty 45% premium for these u.s. assets. but if they can justify what this means for their cash generation prospects and also from a portfolio perspective, astrazeneca has a much bigger global presence, so the bulls would say that they can take alexion's assets and expand into markets like china, which alexion wouldn't do as well on. >> you know what's interesting, all of a sudden, we've been having a lot of chats about health care and people -- you know, we had a guest on the show last week, he wants to be positioned in health care, typically a defensive sector, but actually, he sees decent opportunity particularly in biotech. i just wonder how much of this deal making that's going on now is a function of anticipation, going into 2021 and the extra regulatory scrutiny that could be coming, particularly with the biden administration in the u.s. remember, there's been a lot of talk about the pricing power that these pharma

how has argentina been able to approve the astrazeneca 0xford vaccine so quickly? a law passed in congress in november, a special law particular lease to approve contracts and disturbed vaccines in argentina. it allows for emergency approval such as the one that has got approved, the astrazeneca vaccine, as well as the russian‘s sputnik vaccine and the pfizer vaccine that is not yet arrived at the country because there is a conflict between the government and the company. they don't agree terms of the potential contract. that is based of how the country managed to get such a quick approval of this vaccine. 22.4 million doses is a lot. it is it? is it enough to vaccinate argentina's most honourable people? not in itself, but you also to take into account that there were around 20 million doses from the sputnik vaccine, and that will be enough for another 10 million people, so 11 million from astrazeneca's vaccine, plus 10 million from sputnik‘s vaccine, that should give you around 21 million people vaccinated. that might be just enough, but the diseases quickly

the uk gives approval for the astrazeneca vaccine — with the firstjabs due to begin next week. it's a moment to celebrate and have some optimism about where we've got to today and moving forward. the uk and eu sign an historic trade agreement, after british mps give overwhelming backing to borisjohnson‘s brexit deal. hello and welcome if you're watching here in the uk and around the world. millions more people in england are entering tougher restrictions for covid—19 as the second wave of the virus continues to spread at an alarming rate. the uk authorities have announced a further 50,023 new infections recorded in the latest 2a hours. the average number of new cases reported per day in the last week is nowjust over 40,000. 981 deaths were reported — that's people who died within 28 days of a positive covid—19 test. it means on average in the past week, 500 deaths were announced every day. amidst the terrible toll the virus is taking, there was other news which gives hope for the future. the uk medicines regulator gave the go—ahead for the oxford astrazeneca vaccine,

the vaccine uses a covid-19 vaccine astrazeneca. the vaccine uses a gene covid-19 vaccine astrazeneca. the vaccine uses a gene from the spike shaped protein on the surface of coronavirus. this is put inside a modified harmless virus. the vaccine instructs human cells to make the spiked protein, which grants the immune system to create antibodies, which can recognise and destroy coronavirus. it stimulates t cells, which should destroy cells that have become infected. so just which should destroy cells that have become infected. sojust how effective is the vaccine? the latest estimate is it gets 70% protection against covid three weeks after the first dose. the nhs will hold back giving the second dose of all covid vaccines until 12 weeks so more people can get protected. the most pragmatic thing to do is to give as many at—risk people as possible the first dose of the vaccine because we know from three weeks after that first dose there is a very good level of protection and nobody in the clinical trials at that point after their fi

they‘ re planning to trial a combination of the 0xford—astrazeneca and sputnik v vaccines. the trials, to be held in russia, and will involve over—18s, although it's not clear how many people will be involved. 0ur moscow correspondent sarah rainsford has more on that. this is a very intriguing bit of news, given the type of language that we have heard previously and specifically from the russian backers of sputnik five vaccine and astrazeneca, it is not been a warm relationship of words, at least most a very interesting potential collaboration but we have heard when astrazeneca came in the form of a press release, they began recruiting public volunteers to take part in trials and see where they are using the vaccine together with the second jab of the sputnik vaccine could both boost immunities and create better protection against coronavirus and also potentially resolve some problems with accessibility to vaccines around the world generally so you can mix and match the production flows and problems, supplying vaccines to different parts of the world, it is a very interes

overall, where are we on the vaccine for astrazeneca? there was also some very controversial story about astrazeneca also looking at the russians for the vaccine. where exactly are we? sam: let's not forget that russian or chinese, these are developed by scientists and local companies, and doing combination studies is something that we should be doing anyway have startedthey talking about. the combination of the u.k. talked about was the astrazeneca vaccine potentially with the pfizer vaccine. these are all some things to be explored, but where we are with the vaccine, the new information from what we saw that was published last week, that really didn't change anything for me. if anything, it added a few more questions that i need to see another trial report before i understand what is going on with this vaccine. what we do know works, it is just how it works that is very tough to tell. francine: sam, we are also hearing from singapore that they have reached a deal with a maker and will be able to inoculate as the population by the third

we are hearing from astrazeneca, the ceo, saying they can astrazeneca, the ceo, saying they ca n start astrazeneca, the ceo, saying they can start delivering today or tomorrow. we spoke to so many who had taken part in those trials. tell us had taken part in those trials. tell us how it affected people? either side effects, what are they like? -- either side effects. what i was going to say before you interrupted me, we are so grateful to the volunteers who took part. at the start of this we didn't know very much about how this vaccine would form, whether it would work. they put their trust in the science of the vaccine to take part in the trial. until now we have got about 100,000 blood samples from these volunteers that we are using to study to understand more about the immune response. the vaccine does cause minor side—effects around the time of vaccination some people. some will feel they have a mild viral illness in the first day with a sore arm, sometimes their muscle aches and they feel shivery. that usually wears off quickly during the first week. we really haven't seen a maj

they are planning to try a combination of the oxford astrazeneca and nie russian spk v vaccine. although it is not clear how may people wl be involved. our correspondent has more on that. >> this is an intriguing bit of news even the language we have heard previously, specifically from the russian backers of the sputnik v vaccine. it has not exactly been a warm relationship of words, so this is an interestingorotential collion. what we heard from astrazeneca came in the form of a press will start recruiting volunteers in trials to see whether using the oxford astrazeneca vaccine with a second jab of the sputnik vaccine could boost immunity and create better protection against coronavirus and essentially resolve problems with accessibility to vaccines around the world generally. if you can mix andvaatch differenines, that it -- that potentially helps with production flows and problems, supplying vaccines to different parts of t world. it's an interesting potential collaboration. the details are pretty scarce. the company backing the russian vaccine ggests the trials could start a

astrazeneca also trades in london and on the other hand, astrazeneca, these are the year to date by the way, year-to-date prices. they have done well year-to-date especially compared to the ftse. they should have a difficult time today. your today for astrazeneca, you interesting chart here, down 2%. it should get a boost today as it is improved -- approved in the u.k.. 2020 has thrown the issue of equality into sharp focus, the death of george floyd shown a glaring light on the discrimination the black community faces in america well the impact of the coronavirus deepened existing economic inequalities. for more we are joined by our bloomberg quicktake reporter. george floyd, the catalyst that proved. what action has the corporate world taken since then? blackhas been a lot of squares on instagram, what about actual movement? >> that has been key. we did see corporate america and corporations around the world address inequality in the way we have not seen before in the past. more important were the steps they announced they were going to take versus the statement. we saw a lot of movem

the uk medicines regulator has approved the oxford—astrazeneca coronavirus vaccine, paving the way for millions more people to be immunised in the new year. the uk has ordered 100 million doses — enough to vaccinate 50 million people. the vaccine is much easier to transport and store than the pfizer biontech one already in use, and is also much cheaper. 0ur health correspondent anna collinson has the details. approval of the 0xford—astrazeneca vaccine is a huge moment, and with pressure on hospitals intensifying, it could not have come at a better time. this is a really significant moment in the fight against the pandemic, because the vaccine is the way out, and the approval of the 0xford—astrazeneca vaccine brings forward the date at which we are going to bring this pandemic to an end. after cramming years of work into a matter of months, jabs will begin to be administered on monday. this morning, the head of the uk regulator insisted no corners had been cut. the safety of the public always comes first. the mhra's approval has been reached following approval has been reached fol

there is already some preliminary data from the astrazeneca programme, there have beenjust the astrazeneca programme, there have been just two the astrazeneca programme, there have beenjust two hospitalisations in the whole of the clinical trials programme in patients who receive the vaccine. one hospitalisation occurred two days after the vaccine was occurred two days after the vaccine was given so you occurred two days after the vaccine was given so you can occurred two days after the vaccine was given so you can easily work out that the infection occurred before the vaccine was actually administered. and the second occurred ten days after the vaccine was occurred ten days after the vaccine was given and again, ten days is not long enough for a vaccine to work. optimistically, you would say 7—10 days you might get some effects but far more typically it is 14—21 days where the effect of apraxia is going to kick in. so they were not really vaccine preventable hospitalisations and this is encouraging orbit preliminary data —— the effect of a vaccine. the other big thing that jcvi ha

gives approval for the astrazeneca vaccine. optimism about where we havete. gotten to. anchor: the u.k. and e.u. signed a historic trade agreement after britishe mps gcking to the brexit deal. rescuers search for people missing after a landslide in norw. ♪ hello and welcome. millions more people in england arentering tougher strictions. the second wav of the virus continues to sead at an alarming rate. u.k. authorities have announced thousands of new affections -- infections. 981we death reported. on average, in the past week, 500 deaths were announced every day. >> the approval of the astrazeneca vaccine is a fantastic achievement for british science. >> it is a great day. reporter: this ishe vaccine more than any other that willng eventually brioronavirus under control. unlike pfizer's, the astrazeneca vaccine can be transported>> wie second vaccine, we are another step closer in helping to defeat the vus. our clear message is you can have every confidence in the safety and effectiveness and quality of this vaccine. reporter: the vaccine uses a gene from the spike-s

the coronavirus vaccine developed by astrazeneca and oxford university becomes the second vaccine in the uk to receive regulatory approval. the study‘s director says it is a landmark moment. it's a moment to celebrate and to have some optimism about where we've got to today, and moving forward. but we have to keep up this battle against the virus. the government has ordered 100 million doses, enough to vaccinate 50 million people. the health secretary says the first jabs will be given in the new year. today's news is great news for the ability of the vaccine to make us safe. and make us safe faster than we previously could have done. the news comes as more parts of england are to expected be moved into the highest level of coronavirus restrictions, tier 4. eu leaders sign the post—brexit trade deal agreed with britain on the eve of its departure from the eu single market, it will now be flown to london. here, the prime minister is due to start a debate in the house of commons shortly — as he asks mps to back the brexit trade deal in a vote this afternoon we'll have special cove

approves the oxford astrazeneca coronavirus vaccine. the country's health secretary predicts a path out of the pandemic by spring. >>> sounding the alarm. the u.s. president-elect joe biden says the president's vaccine plans are falling short. >>> and an historic vote. scenes of celebration and disappointment as argentina moves to legalize abortion. hello and a very warm welcome to our viewers in the united states and around the world. i'm isa ar

the medicines regulator gave the go—ahead for the oxford astrazeneca vaccine. it isa the oxford astrazeneca vaccine. it is a landmark moment in the fight against coronavirus. other million doses have been available —— made available next week. daw .5 years after britain voted in a referendum to leave european union by gems parliament in london have approved a new free trade deal finalised last week stop prime minister borisjohnson said britain is marking a new beginning in its relationship with the eu. ten people have been injured, one critically, in a landslide that buried houses in aim norwegian municipality north—east of oslo. 11 people are not accounted for. it's not clear if someone caught up in the landslide or simply away when it happened. -- if —— if somewhat well.

storage in normalfridges will the astrazeneca vaccine. storage in normal fridges will make it much easier to deliver here, but particularly in low and middle income countries, which would have struggled to maintain the cold chain at -70 struggled to maintain the cold chain at —70 degrees as required for the pfizer vaccine, but delivering the vaccine will still be a herculean task for all four uk health services, and they will struggle if they are also dealing with surging covid cases. hospitals in london and the south—east are already reporting shortages of critical care beds and even oxygen, so there is an urgent need to get the new variant under control. does the secretary of state recognise that when dealing with a spreading infection, getting ahead of it is critical? only taking action once cases in an area are soaring is simply too late to bring it under control. all three devolved nations are already under level four restrictions to try and prevent the new variant getting a grip and getting out of control, so with greater levels

gives approval for the astrazeneca vaccine. >> it is a moment to celebrate. optimism about where we have gotten to. anchor: the u.k. and e.u. signed a historic trade agreement after british mps give backing to the brexit deal. rescuers search for people missing after a landslide in norway. ♪ hello and welcome. millions more people in england are entering tougher restrictions. the second wave of the virus continues to spread at an arming rate. u.k. authorities have aounced thousands of new affections -- infections. 981 deaths were reported. on avera, in the past week, 500 deaths were announced every day. >> thepproval of the astrazeneca vaccine is a fantastic achievement for british science. >>ay it is a great d reporter: this is the vaccine more than anyther that will eventually bring coronavirus under control. unlike pfizer's, the astrazeneca vaccine can be transported>> wi second vacci are another step closer in helping to defeat the virus. our clear message is you can have every confidence in the safety and effectiveness and quality of this vaccine. repo

astrazeneca is seeing the oxford vaccine is 73% effective, 80% after the second. pfizer—biontech and moderna over 95%, so should people be worried about this? there will not get a choice, none of us will get a choice about which vaccine we have? we also want to remember that those are in trials and sometimes efficacy can be lower in real life situations, so i think between the two choices right now, really, in regular use, will be more similar, so i not be concerned about small differences between the different types of vaccines right now. what would you say to people who are nervous about vaccines anyway, who are seeing things by many of us have no idea of what we're seeing as misinformation or truth? look up reputable sources, people you trust. i see a lot of my friends who are healthcare professionals who are sessions, scientist and the front lines were getting vaccinated themselves, so i think when you have that kind of confidence among people who are most closely involved with this type of science in these type of trials and to have seen covid on the front

unlike pfizer's, which needs ultra low temperatures, the oxford astrazeneca vaccine can be transported in a fridge, meaning every care home in the uk should now be in reach. the medicines regulator said no corners had been cut. with this approval of the second vaccine, we are another step closer in helping to defeat this virus. 0ur clear message is that you can have every confidence in the safety, in the effectiveness and in the quality of covid—19 vaccine astrazeneca. the vaccine uses a gene from the spike shaped protein on the surface of coronavirus. this is put inside a modified harmless virus. the vaccine instructs human cells to make the spike protein, which prompts the immune system to create antibodies, which can recognise and destroy coronavirus. and it stimulates t—cells, which should destroy cells that have become infected. so just how effective is the vaccine? the latest estimate is it gives 70% protection against covid three weeks after the first dose. the nhs will now hold back giving the second dose of all covid vaccines until 12 weeks so more people can get protected

astrazeneca is seeing the oxford vaccine is 73% effective, 80% after the second. isa biontech over 95%, so second. isa biontech over 95%, so should people be worried about this? there will not get about this? there will not get a choice, none of us will get a choice about which vaccine we have? we also want to remember that those are in trials and sometimes efficacy can be lower in real life situations, so i think between the two choices right now, really, in regular use, will be more similar, so i not be concerned about small differences between the different types of vaccines right now. what would you say to people who are nervous about vaccines anyway, who are seeing things by many of us have no idea of what we're seeing as misinformation or truth? look up misinformation or truth? look up reputable sources, people you trust. i see a lot of my friends who are healthcare professionals who are sessions, scientist and the front lines we re scientist and the front lines were getting vaccinated themselves, so i think when you have that kind of confidence among people

approved a vaccine developed i oxford university and astrazeneca. the pharmaceutical giant pledged to make 1.3 billion doses available at cost to low and middle income countries. we have more from london. correspondent: if ever good news was needed in the u.k., it is now. numbers of new infections and hospitalizations are breaking records. daily deaths are almost as numerous as the daily peak in april, and clinics are sounding alarms that the health service is struggling to cope with the covid wave. a new announcement from the u.k. medicine regulator. >> the covid-19 vaccine from astrazeneca has been approved for people ages 18 and older with two standard doses, four to 12 weeks apart. correspondent: rollout begins january 4, with the oxford astrazeneca vaccine joining that have pfizer and biontech in use in the u.k. since december. both have advantages. at this london vaccination center, you can see the infrastructure needed to administer the pfizer biontech vaccine. you can hear the generators running, people need to be kept warm in the vaccine ne

>> certainly not with regards to astrazeneca. they had their first data back in november so whoever is looking at the data is taking their time to analyze it. trial,u run a clinical you should set up your hypothesis at the beginning of the trial. you cannot go inside the trailer and dig for data that is more pleasing. that is a problem. i'm not assuming that that's what they have done. let's reserve judgment on so -- until we see the data but i understand we are dealing with a difficult pandemic. guy: in terms of the impact of the astrazeneca vaccine in terms of distribution, can you walk me through the mechanics and how much simpler the mechanics are associating with this vaccine? it's stored in a refrigerator? villagecal gp in the can manage to store it. this makes anna norma's difference. we just have to make ourselves comfortable as to the efficacy of the vaccine. frankly, even at 70 or 60%, it's still a powerful tool given that , overuce the severity 90%. i would be happy to see that but we have to be careful how we position

approves the oxford astrazeneca coronavirus vaccine. the country's health secretary predicts a path out of the pandemic by spring. >>> sounding the alarm. the u.s. president-elect joe biden says the president's vaccine plans are falling short. >>> and an historic vote. scenes of celebration and disappointment as argentina moves to legalize abortion. hello and a very warm welcome to our viewers in the united states and around the world. i'm isa suarez. "cnn newsroom" starts right now. >>> this is cnn breaking news. >>> it is 9 a.m. here in london and we start this hour with breaking news out of the u.k. where the government says regulators have approved the oxford astrazeneca coronavirus vaccine. it becomes the second vaccine authorized for use here in the u.k. the british prime minister is celebrating the approval. it is truly fantastic news and a triumph for british science that the oxford astrazeneca vaccine has been approved for use. we will work to vaccinate as many people as possible. cnn's phil black joins me here in london with t

the uk government has approved the astrazeneca oxford covid-19 vaccine. first doses are being released today so that vaccinations will begin early in the new year. it added that it aims to supply millions of doses in the first quarter as part of its deal with the uk government it supply up to 100 million doses in total. shares are up on the development. in other vaccine news, moderna says that it will offer its new covid-19 treatment to its own employees, contractors and board members according to the "wall street journal" oig, t, the com says it is aimed at providing an additional layer of protection to workers delivering the vaccine and that the program would be separate from the doses committed to the u.s. government and chinese vaccine developer sinopharm said interim results showed a 79% efficacy rate the result clears the minimum requirements for chinese regulators and the group has applied for market approval. >>> and hedge fund manager reportedly eyeing a move into venture capital, according to the financial "times," loeb's third point is raising

today the uk medicines regulator gave the go—ahead for the oxford astrazeneca vaccine — signalling a landmark moment in the fight against coronavirus. it comes as the uk announced a further 981 deaths in the past 2a hours — the highest figure since april. here is our medical editor, fergus walsh. the approval of the oxford vaccine, which is a fantastic achievement for british science... it's a great day, we are very proud. this is a really significant moment in the fight against this pandemic. it is, i think, again, a changing moment. this is the vaccine — more than any other — that will eventually bring coronavirus under control. unlike pfizer's, which needs ultra low temperatures, the oxford astrazeneca vaccine can be transported in a fridge, meaning every care home in the uk should now be in reach. the medicines regulator said no corners had been cut. with this approval of the second vaccine, we are another step closer in helping to defeat this virus. our clear message is that you can have every confidence in the safety, in the effectiveness and in the quality of covid—19

astrazeneca compared to others, thingsey have done good an fixing a price -- astrazeneca says $4. for developing countries, probably three dollars per dose. so six dollars per person per course. -- young is, this is can't leave the decision on supply, price, which country, which patiento companies. that is not their job. their job is to produce most of the job government is to make more production so you have to enable otherroducers like in india -- other countries. --if you allow technology sharing technology, which technology, by the way, a lot of it has been developed by public money, including from the u.s. d u.k. and europe and other countries. so allowing the sharing of technology and removing the intellectual property barrier, so no patent on vaccines, than other companies can produce the vaccine and we have more. and just like astrazeneca did contracts with serum that includes presumably technology transfer, that can be done on a multilevel -- multinational level, bigger level for more companies. this deal, by the way, you don't know what is in it except what they announce

of the astrazeneca oxford vaccine. accelerate its vaccination program, how big an economic impact do you think that will have? how big an advantage? >> we are in a race against a mutant strain of covid, and the impact that is having on the southeast of england is immense. the economic impact that is going to have could also big pretty big -- could also be pretty big, too. it may not help for the first couple of months enough to really avoid the economic impact of this extended lockdown that i think we are going to see. maybe we get to the spring and we get enough people vaccinated to start coming out of this kind of broad lockdown, we start moving down through the tears, maybe late february, march, and maybe back into a normal situation in april. everything we have seen from this vaccine from march last year has told us that it takes much longer than you would expect. that there will be surprises along the way that will largely not be pleasant, and i think that's what we have to prepare ourselves for. i'm afraid that r

astrazeneca, i believe it's 300 million on astrazeneca. ok. so, we believe when you take 330 million americans, you take off the nonindicated populations of about 70 million people below age 16, if you just do the math on that, we've got now the vaccine contracted for with delivery, we believe subject, of course, to moderna approval and success of adding in either a johnson & johnson or astrazeneca, we believe that we will have actually surplus supplies of vaccine. that's why the president signed his executive order that made the commitment that we will take that surplus capacity, not just vaccine by manufacturing capacity, and use that for the benefit of the world community. ne last question, michael. >> last question comes from lee ann with cbs news. your line is now open. reporter: thank you, good morning. i'm curious about working with pfizer to increase capacity. are there any shortages of supplies such as reagents? is there request to invoke the defense production act to help them acquire that? a quick note, i'm curious about he christma

at the same time, regulators have approved the astrazeneca vaccine for use. it is expected to roll out next week, and we spoke to the u.k.'s covid vaccine deployment minister. here he is. >> we have begun vaccinations on the eighth of december with the and webiontech vaccine, have vaccinated over 600,000 of the most learnable people in the united kingdom -- most vulnerable people in the united kingdom to the covid-19 virus. we will continue now with both vaccines, pfizer and with astrazeneca approval. today, we start vaccination with that vaccine as of monday, and we have 500 30,000 doses of the astrazeneca for the first week -- from the fourth of january, from the first week, and then we increase the numbers. quicklypendent on how we can vaccinate through the joint committee have set, so that we can take the most honorable. the good news from the regulator is that the time period between -- for both vaccines, we have 12 weeks, which we plan to do so before january. then, we mac -- we will vaccinate more people quickly and get to a place where we can take awa

the oxford astrazeneca one would speed it up enormously. you still run into how many people are available to give the vaccinations. there is no question it would add speed. i think people are almost taking .hat for volatile anxious on the help already. guy: let's talk about a couple of issues to come up in the next couple of days. what is the tolerance of the british population for a tier five? it was talked about yesterday in the media as a possibility because the new variance is causing the old numbers to spike and we have the post christmas spike to deal with as well. in such a scenario, do you think gove,johnson, michael gavin williamson would be able to shut secondary stores possibly for a month? what do you think the tolerance is for that? public: i think the tolerance for tighter restrictions or continuing , people arerictions exhausted, they are afraid. the stories of the strains on livelihoods, mental health, all of that is growing. i think people would absolutely get behind it. the secondary schools is a really difficult one. it a

pushing against the idea that astrazeneca could be a takeover target. this is very much a defensive play, isn't it? rachel: there is that element as well. we have seen him over the last few years really tear down astrazeneca's focus. he called a halt to development programs that work too costly. he has pared down areas for the company to focus on the core areas of innovation, especially in oncology. like you said in the global pharmaceutical sphere, there are really only these top guys. offers, thetakeover latest with pfizer about six years ago. astrazeneca wants to survive and be one of the biggest players, and that basically means take over others. eat or be eaten. manus: thank you so much. let's see how they trade on the opening. will alexian flush out another bidder? we will cover that trade for you. optimistic for the first time in three months. says positivity is misplaced. he says did not wait until christmas to shed your excess pine. david: it is very hard to believe an extension. ofseems as though the 31st december this year is a hard deadline.

approves astrazeneca vaccine, india sets to follow. this is the first reported case of the new variant is found in colorado. the eu and china are expected to confirm their much-anticipated treaty, a move that risks upsetting the upcoming biden administration. for francineson in lacqua and tom keene. both have the day off. let's catch up with the first world news, ritika gupta. ritika: mitch mcconnell rebuffing democrats and president trump on relief checks. he is blocking attempts to force action that would increase direct stimulus payments to $2000. the president weren't failing to act now amounted to a death wish by republicans. a variant of coronavirus that emerged in the u.k. has been found in the u.s., raising concern that a more transmissible strain could spread widely across the country. a man in his 20's in colorado was the first known to be infected with the mutated strain of the virus. he has no reason travel history. in germany, the daily death toll has passed 1000 for the first time. there were more than 1100 deaths there i

the approval of the oxford astrazeneca vaccine, which is a fantastic achievement for british science. it's a great day, we're very proud. this is a really significant moment in the fight against this pandemic. it is, i think, a game—changing moment. this is the vaccine, more than any other, that will eventually bring coronavirus under control. unlike pfizer's, which needs ultra low temperatures, the oxford astrazeneca vaccine can be transported in a fridge, meaning every care home in the uk should now be in reach. the medicines regulator said no corners had been cut. with this approval of the second vaccine, we are another step closer in helping to defeat this virus. our clear message is that you can have every confidence in the safety, in the effectiveness and in the quality of covid—19 vaccine astrazeneca. the vaccine uses a gene from the spike—shaped protein on the surface of coronavirus. this is put inside a modified, harmless virus. the vaccine instructs human cells to make the spike protein, which prompts the immune system to create antibodies which can recognise and destr

so by swapping out the ad5 for the astrazeneca adenovirus vaccine, the astrazeneca—oxford vaccine, that would actually make a lot of sense in terms of producing a safer and possibly more what we call immunogenic vaccine — that's point one. and from a regulatory point of view, the russians have had a number of issues in terms of quality and quality assurance and meeting standards that one would ordinarily expect for the uk and the us, and so by partnering now with astrazeneca—oxford, i think it will lift — lift their boat a lot and make a better vaccine for not only for russia, but they're aggressively trying to export it and make a better vaccine for the world. you talk about lifting the boat for them but of course, the oxford—astrazenica vaccine has, in the us, has come in for criticism about the way it is communicated, about some of the way the data of its trials have been released. do you share any of those concerns? you know, ultimately, i think, it's — well, first of all, we need this vaccine to work and the us cannot vaccinate our population just with the two mrna vaccin

astrazeneca, i believe it's 300 million on astrazeneca. >> you can finish watching this at c-span.org. we'll leave here to fulfill our 40-plus year commitment to congressional conching. -- coverage. the u.s. house about to gavel in. first up, speeches, legislative work starts at 2:00 p.m. eastern. six bills on the calendar today.

the continued spread of the virus could soon be slowed by a second vaccine, from astrazeneca, which has been approved. ireland's prime minister has announced a return to lockdown during january. ireland has extended a ban on travel from britain, blaming increased cases of covid—19 on the new variant first identified in the uk. borisjohnson has signed britain's post—brexit trade agreement with the european union. in brussels, ursula von der leyen signed the deal on behalf of the eu. the agreement also won the backing of the house of commons. and rescuers in norway are still searching for people missing following a landslide. houses were crushed and buried in mud after the landslide hit a village near oslo after heavy rain. hello, and welcome to our look ahead to what the papers will be bringing us tomorrow. with me are sam lister, deputy political editor at the daily express, and lizzy buchan, political correspondent at the daily mirror. tomorrow's front pages, starting with. .. the daily telegraph reports that borisjohnson has said britain is in a race to roll out a freshly approved

so by swapping out the ad5 for the astrazeneca adenovirus vaccine, the astrazeneca—oxford vaccine, that would actually make a lot of sense in terms of producing a safer and possibly more what we call immunogenic vaccine — that's point one. and from a regulatory point of view, the russians have had a number of issues in terms of quality and quality assurance and meeting standards that one would ordinarily expect for the uk and the us, and so by partnering now with astrazeneca—oxford, i think it will lift — lift their boat a lot and make a better vaccine for not only for russia, but they're aggressively trying to export it and make a better vaccine for the world. you talk about lifting the boat for them but of course, the 0xford—astrazenica vaccine has, in the us, has come in for criticism about the way it is communicated, about some of the way the data of its trials have been released. do you share any of those concerns? you know, ultimately, i think, it's — well, first of all, we need this vaccine to work and the us cannot vaccinate our population just with the two mrna vaccin

astrazeneca and the nhs. and so this is really good news this morning, that the vaccine has notjust been approved, but also, that if they find that the immunity to the disease comes after around a fortnight after the first dose, which means that we can really accelerate the number of people who get protected. speaking during a data briefing at downing street earlier, the chair of the human medicine expert working group explained how the doses of the vaccine will be administered. what we are approving is that two standard doses should be given. they should be given at an interval of between four to 12 weeks, are you that there should be an interval of four to 12 weeks between the first and second dose. we also looked at the half dose regimen which has been publicised widely but we felt that the results were not borne out by the results were not borne out by the full analysis. we have come to the full analysis. we have come to the decision of an interval of between four to 12 weeks based on the data that was pr

is poised to approve the astrazeneca vaccine. corontest on the manus: it is your monday edition of daybreak: europe. she is annmarie hordern in london. a bit of a tech blowout this morning. theaba, juliette saly said ant group has been told to get back into its link. this is alibaba. down a .4%. the message from the central into your- get back own lane and stick to payments. ant group has wealth management, billione, a half a customers. not a gazillion. the fallout is all around the tech space. a gazillion. there you go. that is why people tune in to daybreak europe. arehe united kingdom, they running a coordinated vaccination campaign. months to vaccine enough people to have an impact on the spread of the disease that the european commission president says it will be a gradual process and caution is still needed. annmarie: this comes as the united kingdom is poised to approve the covid-19 vaccine reduced by astrazeneca and the university of oxford. the shot could be cleared for use early this week. it is more easily transferred

, they bought a lot more of astrazeneca than any others. the others were kind of in the 100 million range. i guess i don't quite y for astrazeneca they purchased 300 million. everybody else, they purchased 100 million. do you have any idea why? >> yes, because astrazeneca is a low-cost vaccine, and it's basically -- i think they were selling it at no profit. so, the amount of money that the government was clunking down was about the same. but astrazeneca also is not -- there are some questions about its data, its transparency. its trial in the u.s. is not in the same position as pfizer and moderna. what we have in hand ruth now is 100 million doses from moderna, 100 million doses from pfizer. and these are both two-dose regimes, right? so, together they're going to cover 100 million americans. and the question is, you know, who's going to cover the other 230 million. >> sanjay, that is a great question. on good morning america, they said it would not be reasonable to purchase more doses over the summer. another official said that decision w

astrazeneca oxford university shots gained approval yesterday. the capacity to effectively deliver the vaccines from pfizer and astrazeneca. zeneca canof after potentially manufacture to million doses a week. we have the infrastructure to deploy that. at the moment my limitation is the speed at which we can get deliveries from both astrazeneca and pfizer, not the infrastructure. joining us now is bloomberg's emma chandra, who spoke with the minister. more restrictions for more of england. what exactly is the scope? toa: 20 million people added the tier four restrictions, meaning 78% of the english population is facing the toughest restrictions in the u.k., and those tough restrictions -- tier four is similar to the lockdown to what we saw in the virus back in march and april of last year, all essential businesses are closed, people encouraged to stay home, to only leave home for emergencies when they have to travel for work. we are hearing that schools are delaying opening across england after the christmas holiday. that is secondary schools here

today the uk medicines regulator gave the go—ahead for the oxford astrazeneca vaccine — signalling a landmark moment in the fight against coronavirus. it comes as the uk announced a further 981 deaths in the past 2a hours — the highest figure since april. but as the news of the vaccine was received, it was also announced that roughly 20 million more people across england are set to join the toughest tier 4 covid restrictions. from midnight tonight, the midlands, north east, parts of the north west and parts of the south west are among those escalated to tier 4 — with people asked to stay at home and in another of today's announcements — it was confirmed that the reopening of secondary schools in england will be delayed untiljanuary 18th for most pupils. however most primary schools will go back as planned. meanwhile, in the republic of ireland, what's been described as "full scale" level five restrictions, will be reimposed untiljanuary 31st in a bid to contain the spread of covid—19. but first — on the approval of the oxford astrazeneca vaccine and what it means for the uk

now we're seeing some of the astrazeneca data. it doesn't look as effective, necessarily, as the pfizer one which was over 95% effective. but 70% effective it appears. 90% if you gave a low dose, a sort of prime dose followed by a full dose. and, you know, it's a pretty extensive trial. four trials across three continents. what i heard in our own reporting now, kate, is that by middle to end of january we're likely to hear astrazeneca also applying for an emergency use authorization. we're likely to here about a division of johnson & johnson also applying. add this all together, kate, and you could have potentially four vaccines authorized by february of next year. and that's when you start to get into the real numbers of possibly being able to vaccinate the country. >> and that's why this rollout, this massive effort is so important to get right when you see all these vaccines could be coming online quickly in quick succession. thank you, sanjay. >> you got it. >>> i want to turn to the white house where there's a dispute with th

we know in the astrazeneca trial they looked at asymptomatic infection. that is not a direct measure of transmission, but if people are not developing asymptomatic infection, it is unlikely they will be transmitting, or their probability of transmission will be low. i think we will get some information, but we are going to need to set up additional studies to look at this. what we pandemic, in are going to see, there is going to be so much transmission in the united states that i expect we will be able to see this. people have been talking about setting up studies in college dormitories to look directly at transmission. part of the answer is going to come from the current trials, partly from new studies. we will probably have a good handle on that question by mid-2021, if not a couple months sooner. from: the next question is alan greenblatt governing. can you comment on the challenge involved in distribution? what role do you see government playing? do you feel they are prepared? dr. limaye: it is a great question. with the introduction of new types of v

like astrazeneca it's easy to store and inexpensive. johnson & johnson is wrapping up trials at stanford and the va. ucsf epidemiologist dr. george rutherford expects promising data early next year. >> the good news from johnson & johnson they've increased their trial up to 40,000 people. you don't do that unless you're expecting a large affect. >> reporter: astrazeneca's efficacy varies depending on dosage but overall data shows it's 70% effective. ucsf infectious disease specialist dr. chin-hong proves it was 50%. >> these are amazing vaccines. you pass the test. >> reporter: for context the measles vaccine and gold standard is 97% effective after two doses. flu vaccine efficacies vary season to season but on average the past ten years flu vaccines have been about 44% effective. >> right now 60% of americans say they will get the vaccine, but we need it to be 70%. hopefully that number will increase. >> eporter: pfizer, moderna and astrazeneca require two doses. pfizer is 52% after the first dose. why is it so important to follow one